Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 11/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 10/20 | 1.00 |
| ▸ | BCL2 | P10415 | 9/20 | 1.00 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 1.00 |
| ▸ | ALB | P02768 | 4/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.50 |
| ▸ | LDHA | P00338 | 2/20 | 0.50 |
| ▸ | LDHB | P07195 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apogossypol SCHEMBL2513478 | 1.00 | BCL2L1 (1.00) | BCL2L1MCL1BCL2BCL2L2ALB | |
| Apogossypol SCHEMBL29353524 | 1.00 | BCL2L1 (1.00) | BCL2L1MCL1BCL2BCL2L2ALB | |
| SCHEMBL12200184 | 0.96 | BCL2L1 (0.93) | BCL2L1MCL1BCL2BCL2L2ALB | |
| SCHEMBL14958609 | 0.93 | MCL1 (0.87) | BCL2L1MCL1BCL2BCL2L2ALB | |
| SCHEMBL30143373 | 0.88 | MCL1 (0.77) | BCL2L1MCL1BCL2BCL2L2ALB | |
| SCHEMBL14959261 | 0.88 | MCL1 (0.77) | BCL2L1MCL1BCL2BCL2L2ALB | |
| SCHEMBL30143506 | 0.88 | MCL1 (0.77) | BCL2L1MCL1BCL2BCL2L2ALB | |
| SCHEMBL22700667 | 0.83 | MCL1 (0.69) | BCL2L1MCL1BCL2BCL2L2ALB | |
| SCHEMBL14995993 | 0.83 | BCL2L1 (0.71) | BCL2L1MCL1BCL2BCL2L2BCL2A1 | |
| SCHEMBL17372966 | 0.82 | MCL1 (0.82) | BCL2L1MCL1BCL2BCL2L2ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230025865-A1 | COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF Bcl-2 AND Bcl-xL ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-01-26 | — | — | US | claimed |
| CN-114786654-A | Compositions and methods for systemic delivery of Bcl-2 and Bcl-xL antagonists | 密执安大学评议会 | 2022-07-22 | — | — | CN | claimed |
| US-20220162561-A1 | COMPOSITION FOR PROMOTING SECRETION OF EXTRACELLULAR VESICLES | NISSAN CHEMICAL CORPORATION (JP) | 2022-05-26 | — | — | US | claimed |
| US-20230025865-A1 | COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF Bcl-2 AND Bcl-xL ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-01-26 | — | — | US | disclosed |
| US-20220162561-A1 | COMPOSITION FOR PROMOTING SECRETION OF EXTRACELLULAR VESICLES | NISSAN CHEMICAL CORPORATION (JP) | 2022-05-26 | — | — | US | disclosed |
| CN-114315673-A | Gossypol-selenocysteine Schiff base compound and synthetic method and application thereof | 陕西科技大学 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025865-A1 | COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF Bcl-2 AND Bcl-xL ANTAGONISTS | BCL2, BCL2L2, BCL2L1 | BCL2L1 3/4885MCL1 10/4885BCL2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.